GTX Inc

GTXI NASDAQ
0.9850
-0.0450
-4.37%
已收盘, 17:20 05/23 EDT
开盘
1.020
昨收
1.030
最高
1.030
最低
0.9500
成交量
20.54万
成交均量(3M)
75.20万
52周最高
25.60
52周最低
0.7400
换手率
0.85%
市值
2,369.11万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供GTX Inc GTXI股票价格,GTX Inc股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.
展开 >

最近浏览

名称
价格
涨跌幅